聚烯酸 (Poly) /聚乙烯醇 (Poly) 微阵列贴片用于连续通过皮肤输送利沃多巴和卡比多巴:体外和体外研究
Yaocun Li1, Lalitkumar K Vora1, Jiawen Wang1
1School of Pharmacy, Queen's University Belfast, 97 Lisburn Road, Belfast BT9 7BL, UK.
Pharmaceutics
|May 25, 2024
概括
溶解微针贴片为帕金森病提供了一种最少的侵入性方法来输送莱沃多巴和卡比多巴,绕过口服途径和手术. 这种方法确保了连续的药物输送,具有与口服悬浮剂可比的生物可用性.
科学领域:
- 制药科学 制药科学
- 生物材料工程 生物材料工程
- 药理学 药理学是指药理学的学科.
背景情况:
- 利沃多巴 (LD) 是帕金森病 (PD) 的黄金标准,但由于药理动力学波动,口服导致运动并发症.
- 目前的连续输送选择,如杜多巴,需要进行侵入性手术,这可能会导致终身并发症的风险.
- 溶解微针贴片 (MAP) 是通过皮肤输送药物的一种最小侵入性的替代方案,绕过胃肠道.
研究的目的:
- 探索溶解MAP的潜力,以便通过皮肤输送利沃多巴 (LD) 和卡比多巴 (CD).
- 开发和描述MAP,以持续和同时提供LD和CD.
- 评估通过溶解MAPs传递的LD和CD的体内药理动力学和生物可用性.
主要方法:
- 使用酸性聚合物,聚烯酸 (PAA) 制造溶解MAP,以稳定LD.
- 在制定的MAP中量化LD和CD药物负载.
- 在Sprague-Dawley大鼠体内药理学研究,将溶解的MAP与口服LD/CD悬浮剂进行比较.
主要成果:
- 配制的MAP含有1.82 ± 0.24毫克的LD和0.47 ± 0.04毫克的CD.
- 溶解MAPs证明了LD和CD的同时交付.
- 在体内研究显示,曲线下面积 (AUC) 值与口服悬浮剂相当,相对生物利用率约为37.22%.
结论:
- 溶解MAP是一种可行的,微创的策略,用于通过皮肤输送利沃多巴和卡比多巴.
- 这种方法为持续的PD药物治疗提供了口服和侵入性手术方法的潜在替代方案.
- 微针贴片技术有望通过确保在没有手术的情况下保持一致的药物水平来改善帕金森病的管理.
相关概念视频
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
01:22Modified-Release Drug Delivery Systems: Rate-Programmed I
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
01:30Modified-Release Drug Delivery Systems: Stimuli-Activated
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also called...
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
01:26Oral Drug Delivery Systems: Continuous-Release Systems
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
01:18Transdermal Drug Delivery Systems
Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...